Survodutide is an experimental peptide from Boehringer Ingelheim that activates the receptors for two hormones, glucagon and GLP-1.1,3 It is not FDA-approved, and FDA has warned companies that sold unapproved drugs containing survodutide falsely labeled as being for research purposes.2 Published randomized trials report weight loss in obesity, including the 725-person Phase 3 SYNCHRONIZE-1 trial, and improvements in liver measures in people with fatty liver disease.4,5,6
Survodutide at a glance
What it is
An investigational glucagon receptor and GLP-1 receptor dual agonist from Boehringer Ingelheim, also known as BI 456906.1,3
FDA status
Not FDA-approved. FDA lists survodutide among unapproved drugs it has warned companies for selling with false research-use labels.2
Human evidence
Randomized trials reported in journals: two Phase 2 trials and two Phase 3 trials. A completed cardiovascular safety trial and other Phase 3 trials are registered.3,4,5,6,7
Evidence strength
Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned
What is survodutide?
Survodutide, also known as BI 456906, is an experimental peptide being developed by Boehringer Ingelheim, which ClinicalTrials.gov lists as the sponsor of the trial record cited on this profile.1
The Phase 2 obesity trial report describes it as a glucagon receptor and GLP-1 receptor dual agonist.3
How is survodutide thought to work?
Survodutide is designed to act on two hormone receptors at once: the GLP-1 receptor and the glucagon receptor.3
A Boehringer Ingelheim trial registered on ClinicalTrials.gov compares survodutide with semaglutide on glucagon receptor activity in the liver.1
The sources reviewed here do not establish how much each receptor contributes to the effects reported in trials.3,5
What do human studies show?
In SYNCHRONIZE-1, a Phase 3 trial of 725 adults with obesity, or overweight with a related condition, and no diabetes, average weight change at 76 weeks was −12.2% and −13.0% in the two survodutide groups, compared with −5.4% with placebo.5
Gastrointestinal events occurred in 80.9% and 89.7% of the survodutide groups and 47.9% of the placebo group in that trial, and no deaths were reported.5
In the earlier Phase 2 obesity trial of 386 adults, average weight change over 46 weeks ranged from −6.2% to −14.9% across the planned survodutide groups, compared with −2.8% with placebo. About 60% of participants completed the treatment period.3
In a Phase 2 trial of 293 adults with biopsy-confirmed MASH and liver fibrosis, improvement in MASH without worsening fibrosis was reported in 43% to 62% across the survodutide groups and 14% with placebo after 48 weeks.4
In SYNCHRONIZE-MASLD, 68.5% of the survodutide group and 28.6% of the placebo group reached at least a 30% reduction in liver fat measured by MRI at 48 weeks. MRI liver fat is not the same as fewer liver-related illnesses or deaths.6
What the evidence base contains
Large randomized human trial SYNCHRONIZE-1, a 76-week blinded, randomized, placebo-controlled Phase 3 trial in 725 adults with obesity, or overweight with a related condition, that excluded diabetes, published in The New England Journal of Medicine.5
Large randomized human trial A 46-week randomized, double-blind, placebo-controlled Phase 2 trial that treated 386 adults with overweight or obesity without diabetes, published in The Lancet Diabetes & Endocrinology.3
Controlled human trial A 48-week randomized, placebo-controlled Phase 2 trial that treated 293 adults with biopsy-confirmed MASH and liver fibrosis, published in The New England Journal of Medicine.4
Controlled human trial SYNCHRONIZE-MASLD, a 48-week blinded, randomized, placebo-controlled Phase 3 trial in 216 treated adults with obesity and fatty liver disease, published in Nature Medicine.6
Registered trial without results SYNCHRONIZE-CVOT (NCT06077864), a Phase 3 cardiovascular safety trial in people with overweight or obesity, listed as completed in its August 11, 2026 registry record. Its results are not part of the sources cited here.7
No. Survodutide remains in clinical trials. None of the sources reviewed here reports an approval of survodutide in any country.1,2,9
FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, says FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled as being for research purposes or not for human consumption.2
FDA says these products have been sold directly to consumers for human use, and it urges consumers to avoid them because they are of unknown quality.2
Boehringer Ingelheim has registered further Phase 3 trials, including a MASH trial that was recruiting and a type 2 diabetes trial that was not yet recruiting in their August 10, 2026 registry records.8,9
Timeline
Results of Phase 2 trials in obesity and in MASH with fibrosis are published.3,4
Results of the Phase 3 trials SYNCHRONIZE-1 and SYNCHRONIZE-MASLD are published.5,6
FDA’s page on unapproved GLP-1 drugs, which names survodutide among drugs sold with false research-use labels, is updated, as shown by its content-current date.2
What is still unknown?
Whether survodutide is safe for the heart over the long term: the SYNCHRONIZE-CVOT trial is listed as completed, but its results are not part of the sources cited here.7
Whether its liver-fat and liver-tissue changes lead to fewer liver-related illnesses or deaths, which the trials reviewed here were not designed to show.4,6
Whether weight loss is maintained after treatment stops, and how often less common harms occur over longer periods.3,5
What is in survodutide products marketed outside clinical trials, which FDA describes as unapproved and of unknown quality.2
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Survodutide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Survodutide are the records PeptideScanner has selected and published, not every registration or paper about Survodutide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
In clinical trials; not FDA-approved. Published randomized trials, including the Phase 3 SYNCHRONIZE-1 trial, report weight loss and liver-fat reductions. A completed cardiovascular safety trial has no results in the cited sources. FDA has warned companies selling unapproved survodutide with false research-use labels.↗↗↗↗↗↗
Four selected phase 2 and phase 3 reports examine survodutide in obesity and liver disease. Weight, MRI liver-fat and histological endpoints are different outcomes and should not be treated as interchangeable.↗↗↗↗
What the reviewed sources report
Selected studies reported improvements in weight or liver-related measurements. The newer phase 3 reports also found frequent gastrointestinal adverse events. These measured changes do not establish every long-term clinical benefit, and linked correction notices remain relevant to interpretation.↗↗↗↗
What remains unresolved?
Do Phase 3 trials confirm durable clinical outcomes, clarify fibrosis effects, and characterize harms across broader populations?↗↗
How do participant flow, missing outcomes, protocol history and linked corrections affect interpretation of the selected reports?↗↗↗↗
Four selected phase 2 and phase 3 reports examine survodutide in obesity and liver disease. Weight, MRI liver-fat and histological endpoints are different outcomes and should not be treated as interchangeable.1234
Bottom line from this bounded source set
Selected studies reported improvements in weight or liver-related measurements. The newer phase 3 reports also found frequent gastrointestinal adverse events. These measured changes do not establish every long-term clinical benefit, and linked correction notices remain relevant to interpretation.1234
Reviewed study record
Phase 2 obesity trial
Design
A randomized, double-blind, placebo-controlled dose-finding Phase 2 trial assessed body-weight change over 46 weeks.1
Population
The trial treated 386 adults with overweight or obesity without diabetes across 43 centers in 12 countries.1
Outcomes reported
Reported mean body-weight change ranged from -6.2% to -14.9% across planned survodutide groups and was -2.8% with placebo. About 60% completed the treatment period, and gastrointestinal events were more frequent with survodutide.1
Limitations
The sponsor-funded trial was Phase 2, had substantial treatment-period attrition, and Crossref registers a publisher erratum with two upstream dates for the same notice. Crossref metadata alone does not describe the corrected wording.1
Reviewed study record
Phase 2 MASH and fibrosis trial
Design
A randomized, placebo-controlled Phase 2 trial assessed histologic improvement in steatohepatitis without worsening fibrosis over 48 weeks.2
Population
The trial treated 293 adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and fibrosis stages F1 through F3.2
Outcomes reported
Improvement in steatohepatitis without worsening fibrosis was reported in 43% to 62% across survodutide groups and 14% with placebo. Improvement in fibrosis by at least one stage was reported in 34% to 36% and 22%, respectively.2
Limitations
The sponsor-funded, 48-week Phase 2 trial was not designed to establish long-term liver-related clinical outcomes or uncommon harms, and the fibrosis result was a secondary endpoint.2
Reviewed study record
SYNCHRONIZE-1: phase 3 obesity study
Design
A blinded randomized placebo-controlled trial assessed percentage weight change and at least 5% weight reduction at 76 weeks, under NCT06066515.3
Population
The report describes 725 adults with obesity or overweight with a related complication, excluding diabetes.3
Outcomes reported
The treatment-regimen analysis reported mean weight changes of −12.2% and −13.0% in the active groups versus −5.4% with placebo. Gastrointestinal events occurred in 80.9% and 89.7% of active groups versus 47.9% with placebo.3
Limitations
The analysis includes treatment discontinuation and other specified intercurrent events. Weight reduction does not itself establish fewer cardiovascular events or other long-term complications. No deaths were reported.3
Reviewed study record
SYNCHRONIZE-MASLD: liver-fat and weight endpoints
Design
A blinded randomized placebo-controlled phase 3 study assessed MRI-measured liver-fat reduction and weight change at 48 weeks.4
Population
The abstract describes 216 treated adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease.4
Outcomes reported
Under the treatment-regimen analysis, 68.5% with survodutide and 28.6% with placebo reached at least 30% liver-fat reduction. Mean weight changes were −8.7% and −1.4%, respectively. Gastrointestinal adverse events were common.4
Limitations
The larger estimates in the efficacy analysis answer a different question from the treatment-regimen analysis. MRI liver fat is not a clinical liver-event outcome. A linked publisher correction is recorded with this source; follow-up was short and recruitment was limited to the United States and Spain.4
Publication update registered by CrossrefErratum ↗ · publisher metadata · December 17, 2025 and February 1, 2026. Crossref metadata identifies the notice but does not by itself explain what wording changed.
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2401755. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2600751. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Publication update registered by CrossrefCorrection ↗ · publisher metadata · August 25, 2026. Crossref metadata identifies the notice but does not by itself explain what wording changed.
NCT04667377 records 387 participants in a randomized placebo-controlled phase 2 study. The posted primary analysis reports adjusted mean weight changes from −6.19% to −14.94% across active groups versus −2.82% for placebo. NCT04667377 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
The weight analysis handles discontinuations differently
The registry includes on- and off-treatment measurements for most participants, but uses only on-treatment values after COVID-related early discontinuation. Its estimate is therefore not directly comparable with every trial that excludes all post-discontinuation data. NCT04667377 ↗
Histological improvement is not identical to disease resolution
NCT04771273 studied biopsy-confirmed steatohepatitis with F1–F3 fibrosis. Its primary definition requires a specified activity-score improvement without fibrosis worsening; it does not simply mean complete disease resolution or prevention of liver failure. NCT04771273 ↗
Assigned and actual treatment analyses are separate
The liver-trial registry posts both planned-maintenance and actual-maintenance analyses, with different group denominators. Participants missing post-baseline biopsy data are classified as nonresponders. Selecting a favorable percentage without its analysis definition would be misleading. NCT04771273 ↗
What remains to be checked
Reconcile primary papers and analysis plans with assigned-treatment and actual-treatment registry results.
Review phase 3 and longer-term liver and cardiovascular outcomes separately from phase 2 weight or biopsy endpoints.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
80 retrieved · 4 included · 0 excluded · 76 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Survodutide"[Title/Abstract] OR "BI 456906"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Linked correction notices require comparison with the selected reports: PMID41421369 for PMID38330987. Their presence does not establish what changed.
The selected newer trials are not a completed screen of this entire title/abstract search. Additional primary, secondary, safety and protocol reports remain to be appraised.
Showing 25 of 80 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 42253238 — include: Selected primary trial report; the abstract and record metadata were read. Inclusion is not completed full-text appraisal. Study families: NCT06066515.
PubMed 42252333 — include: Selected primary trial report; the abstract and record metadata were read. Inclusion is not completed full-text appraisal. A linked publisher correction is recorded in the selected review; its interpretation requires the stated correction context. Study families: NCT06309992.
PubMed 38847460 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04771273.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 38330987 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04667377.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
Notice XML SHA-256 a3922bee42ceaa6890ae1b819dc443ef3984b0c5b8e7ad0aba5a34fb819b2514.
PubMed 42683980 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42642663 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42603384 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42599381 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42590128 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42568490 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42545725 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42535526 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42529769 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42331726 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42254697 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42219222 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42208956 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42192439 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41948476 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41855048 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41831171 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41787737 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41704810 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41638399 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41478576 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 0 included · 0 excluded · 1 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 69151 — not screened: Title-name match awaiting identity and document review. P/0259/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for survodutide (EMEA- 002942-PIP02-20-M02)
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
33 retrieved · 0 included · 0 excluded · 33 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
NCT06066515 lists enrollment of 726, while PMID 42253238 describes 725 participants. Participant-flow and registry-history reconciliation remains open.
NCT06309992 lists enrollment of 218; the PMID 42252333 abstract describes 216 treated participants. Enrollment and treated populations are distinct.
Showing 25 of 33 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT04667377 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07407348 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05751226 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07754461 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06066528 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06632444 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05202353 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06564441 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06309992 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06352424 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06176365 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06632457 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06077864 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06745284 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06352411 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06214741 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04771273 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07413913 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06066515 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05296733 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07071974 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07206290 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03591718 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05896384 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06492135 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Survodutide?
In clinical trials; not FDA-approved. Published randomized trials, including the Phase 3 SYNCHRONIZE-1 trial, report weight loss and liver-fat reductions. A completed cardiovascular safety trial has no results in the cited sources. FDA has warned companies selling unapproved survodutide with false research-use labels.↗↗↗↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Status at observationNot yet recruiting 4Completed 3Recruiting 3Active, not recruiting 1
A phase value is unavailable here for 3 selected records; this is not counted as “no phase.”
A status value is unavailable here for 3 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
1 of 4 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesLetter 1
Bibliography fields unavailable here for 3 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
18
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 18 dated records
PeptideScanner retained ClinicalTrials.gov record NCT07940244 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was survodutide.
ClinicalTrials.gov posted a newer version of NCT06077864, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
ClinicalTrials.gov posted a newer version of NCT06632457, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
Selected records span June 25, 2025 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PeptideScanner retained ClinicalTrials.gov record NCT07940244 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07850063 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07850050 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07768813 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07221591 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07855900 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was survodutide.↗
PubMed lists PMID 42897119 in Diabetes, obesity & metabolism as Letter, with publication-date metadata of 2026-10-19 (day precision). PeptideScanner associated the retained record with the identity slug survodutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained ClinicalTrials.gov record NCT06632444 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.↗